Pharmaceutical Business: Pharmaceutical & Biotechnology Industry

NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent in hypertensive patients by Merck & Co., Inc.

Merck plans to conduct a number of clinical studies in hypertensive patients involving single and multiple ascending
dosing, prior to the selection of a compound to be advanced into phase 2....Read More

Merck Wins Reversal of Jury $32 Million Vioxx Award

Merck & Co., the third-largest U.S. drugmaker, won reversal of a $32 million jury award to a Texas family over the death of a former user of the company's withdrawn painkiller Vioxx....Read More

NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent in hypertensive patients by Merck & Co., Inc.

Merck & Co., Inc. has initiated the first in a series of planned clinical studies, in mild to moderate hypertensive patients, under the companies' collaborative agreement to develop new nitric oxide-donating antihypertensive agents using NicOx' proprietary technology....Read More

Roxane Laboratories, Inc. Announces the Launch of Acarbose Tablets

Roxane Laboratories, Inc. announced today the approval of their Abbreviated New Drug Application for Acarbose Tablets....Read More

Teva seeks judgment on Astra\'s Nexium patents

AstraZeneca is confident in the strength of its patent protection regarding Nexium and will vigorously protect its intellectual property," the company said in a statement....Read More

Genentech/Biogen Idec: Rituxan fails Phase II/III SLE trial

Rituxan, the blockbuster drug from Genentech and Biogen Idec, is the latest casualty in the systemic lupus erythematosus indication, reaffirming the complexity of this disease. In a Phase II/III trial, it was unable to demonstrate clinical efficacy in patients with SLE.
...Read More

NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program

NicOx S.A. (Euronext Paris: COX) today announced the results of a U.S. phase 2 study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to Xalatan(R) (latanoprost) 0.005% in patients with primary open-angle glaucoma and ocular hypertension. ...Read More

AstraZeneca CEO touts preventative approach to health care

The American health-care system is in big trouble, David Brennan, chief executive officer of the pharmaceutical giant AstraZeneca told a luncheon audience today in Boston....Read More

Novartis says Menveo improves meningitis immunity

Novartis AG's vaccine Menveo gave improved immunity against four types of meningitis in a late-stage trial when compared with Sanofi-Aventis SA's Menactra, the Swiss drugmaker said on Tuesday....Read More